Covington & Burling and Taylor Wessing advised Draig Therapeutics Limited on the transaction, and Ropes & Gray has advised Sanofi. Draig Therapeutics Limited has secured a...
Draig Therapeutics Secures $140 Million in Total Financing Since Inception
Cumulus Oncology and leadXpro’s Collaboration on GPR68-Targeting Cancer Therapeutics
Taylor Wessing advised Cumulus Oncology Cumulus Oncology on its exclusive GPR68 licence and development collaboration with leadXpro. Cumulus Oncology and leadXpro initiated a groundbreaking collaboration in...
Apollo Therapeutics’ $226.5m Series C Financing
Taylor Wessing advised Apollo Therapeutics on its series C funding round. Apollo Therapeutics Limited, a biopharmaceutical company headquartered in Cambridge, has successfully raised $226.5 million in...
Shield Therapeutics plc’s Transformational Collaboration Agreement With Viatris
Taylor Wessing advised Shield Therapeutics plc on the deal. Shield Therapeutics plc, an AIM-listed commercial stage specialty pharmaceutical company, concluded its transformational collaboration agreement with global...
Nuclera’s Series B Funding Round
Taylor Wessing advised Nuclera on the deal. Nuclera, the pioneer in making biology accessible to everyone through desktop bioprinting, thorugh its Series B financing, raised a...
Nuclera’s Acquisition of Digital Microfluids Unit from E Ink
Sullivan & Worcester advised E Ink on the deal. Taylor Wessing advised Nuclera. E Ink, the leading innovator of electronic ink technology, announced the sale of its...